Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01184599
Other study ID # OCGH-746
Secondary ID
Status Recruiting
Phase Phase 4
First received August 16, 2010
Last updated June 23, 2011
Start date June 2010

Study information

Verified date May 2010
Source Kagawa University
Contact Masahito Imanishi
Phone +81-6-6929-1221
Email masachan@msic.med.osaka-cu.ac.jp
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 75 Years
Eligibility Inclusion Criteria:

- IgA nephropathy confirmed by renal biopsy

- Hypertension (<= 125/75 mmHg)

Exclusion Criteria:

- Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks

- Severe hypertension (<= 180/110 mmHg) or secondary hypertension

- Patients with history of allergy or adverse effect for aliskiren

- Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2)

- Pregnancy

- Patient treated with cyclosporine

- Hyperkalemia (serum potassium >= 5.6 mmol/L)

- Autoimmune disease including systemic lupus erythematosus

- Patients inadequate for the study

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
aliskiren
150 mg/day p.o.

Locations

Country Name City State
Japan Kurume University, School of Medicine Fukuoka
Japan Department of Internal Medicine, Osaka City General Hospital Osaka
Japan Kinki University, Faculty of Medicine Osaka
Japan Ohno memorial Hospital Osaka

Sponsors (1)

Lead Sponsor Collaborator
Kagawa University

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Renal function (Creatinine clearance) One year (every 6 months) No
Primary Urinary protein One year (every 6 months) No
Secondary Urinary angiotensinogen One year (every 6 months) No
Secondary Urinary type 4 collagen One year (every 6 months) No
Secondary Urinary Transforming growth factor-beta One year (every 6 months) No
Secondary High-sensitivity C-reactive protein One year (every 6 months) No
Secondary Plasma Rennin Activity One year (every 12 months) No
Secondary Aldosterone One year (every 12 months) No
Secondary Asymmetric dimethylarginine One year (every 12 months) No
Secondary Advanced glycation end product One year (every 12 months) No
Secondary (Pro)renin receptor One year (every 12 months) No
Secondary Oxidative stress One year (every 12 months) No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A